Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle

• Published in: Vaccines (Basel) Vol. 9; no. 11; p. 1347
• Main Authors: Royal, Joshua M., Simpson, Carrie A., McCormick, Alison A., Phillips, Amanda, Hume, Steve, Morton, Josh, Shepherd, John, Oh, Youngjun, Swope, Kelsi, DeBeauchamp, Jennifer L., Webby, Richard J., Cross, Robert W., Borisevich, Viktoriya, Geisbert, Thomas W., Demarco, Jennifer K., Bratcher, Barry, Haydon, Hugh, Pogue, Gregory P.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 17.11.2021; MDPI
• Subjects: ACE2; Angiotensin-converting enzyme 2; Antigens; Binding; Chromatography; Coronaviruses; COVID-19; COVID-19 vaccines; CpG islands; Disease transmission; Epitopes; Fatalities; Glycoproteins; Humidity; Immunogenicity; Immunoglobulin G; Infections; Influenza; Lymphocytes T; Manufacturing; Monoclonal antibodies; nanoparticle; Nanoparticles; Neutralizing; Pandemics; Pathogens; Peptides; plant-based manufacturing; Proteins; receptor-binding domain; Receptors; Respiratory diseases; SARS-CoV-2 vaccine; Severe acute respiratory syndrome coronavirus 2; Spike glycoprotein; Spike protein; Tobacco; Transmission electron microscopy; Vaccines; Viral diseases; Viruses; United States > US

Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain (RBD) of the spike glycoprotein (S) fused to a huma...